Schrodinger (SDGR) closed at $30.85 on November 12, 2026, down 2.1% from the previous close, on volume of 1,263,531 shares (30-day average 2,160,362).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 16, 2026 | Diagonal Call Spread | 16-Oct : 20-Nov-2627.5 : 25 C | 600 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 11, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Tue, 10-Nov 3:30 PM ET)
Schrdinger Reports Third Quarter 2026 Financial Results
Business Wire (Wed, 4-Nov 4:05 PM ET)
Schrdinger to Present at UBS Global Healthcare Conference
Business Wire (Wed, 28-Oct 8:30 AM ET)
Schrdinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Mon, 26-Oct 8:30 AM ET)
Schrdinger to Announce Third Quarter 2026 Financial Results on November 4
Business Wire (Wed, 21-Oct 8:30 AM ET)
Market Chameleon (Thu, 15-Oct 4:05 AM ET)
Schrdinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry
Business Wire (Wed, 14-Oct 11:05 AM ET)
Schrödinger’s latest inducement RSUs cover just 2,243 shares and vest over four years
Market Chameleon (Fri, 18-Sep 6:31 AM ET)
Schrödinger Highlights 2,243-Share Inducement RSU Grants as SDGR Trades Higher Midday
Market Chameleon (Thu, 17-Sep 7:33 AM ET)
Schrdinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Thu, 17-Sep 8:30 AM ET)
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
Schrodinger trades on the NASDAQ stock market under the symbol SDGR.
As of November 12, 2026, SDGR stock price declined to $30.85 with 1,263,531 million shares trading.
SDGR has a beta of 1.63, meaning it tends to be more sensitive to market movements. SDGR has a correlation of 0.08 to the broad based SPY ETF.
SDGR has a market cap of $2.31 billion. This is considered a Mid Cap stock.
Last quarter Schrodinger reported $64 million in Revenue and -$.50 earnings per share. This beat revenue expectation by $17 million and exceeded earnings estimates by $.16.
In the last 3 years, SDGR traded as high as $38.00 and as low as $10.95.
The top ETF exchange traded funds that SDGR belongs to (by Net Assets): IJR, ARKG, VTI, IWM, VB.
SDGR has outperformed the market in the last year with a price return of +68.6% while the SPY ETF gained +12.0%. SDGR has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +65.4% and -0.1%, respectively, while the SPY returned -1.5% and -2.0%, respectively.
SDGR support price is $29.78 and resistance is $33.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SDGR shares will trade within this expected range on the day.
